An open-label multi-center, randomized Phase II trial of the anti-PD-1 monoclonal antibody nivolumab (Opdivo) versus nivolumab plus bavituximab in patients with previously treated locally advanced or metastatic NSCLC

Trial Profile

An open-label multi-center, randomized Phase II trial of the anti-PD-1 monoclonal antibody nivolumab (Opdivo) versus nivolumab plus bavituximab in patients with previously treated locally advanced or metastatic NSCLC

Planning
Phase of Trial: Phase II

Latest Information Update: 09 Sep 2015

At a glance

  • Drugs Bavituximab (Primary) ; Nivolumab
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Sep 2015 Planned initiation date changed from 1 Jul 2015 to 1 Dec 2015, based on a Peregrine Pharmaceuticals media release.
    • 03 Jun 2015 New trial record
    • 01 Jun 2015 According to a Peregrine media release, the company expects to initiate this trial in the second half of 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top